Posted in | News | Gold | Uranium

Mawson Resources Reports First Channel Sample Results from Rompas Gold-Uranium Project

Mawson Resources Limited (TSX - MAW; Frankfurt - MRY) Mr Michael Hudson, President & CEO, announces the first channel sample results from the Company's 100% owned Rompas gold-uranium project in northern Finland. 

Highlights from 39 surface channel samples include 0.3m @ 1,866 g/t Au and 8.0 % U, and 0.26m @ 1,510 g/t Au and 3.95 % U. The diamond saw-cut channel samples are considered the first representative samples collected at Rompas.

Included in this batch were 10 mineralized grab samples that averaged 672 g/t Au and 2.06 % U and ranged from 0.2 g/t to 3,230 g/t Au and 14.6 ppm to >15% U.  Grab samples are selective by nature and are unlikely to represent average grades on the property.

All samples reported come from Rompas South.  The channels were taken over a strike distance of 75 metres and grab samples over an area of 65m by 125m.  To date, hundreds of gold and uranium showings have been discovered at Rompas over a surface area exceeding 6.5km in strike and 200m average width.  A total of 984 rock chip samples (including 111 highly radioactive samples) remain to be reported by the laboratory from the field program conducted this summer at Rompas.

"This first reported set of representative channel sample results are a milestone for Mawson at Rompas, as they demonstrate the repeated occurrence of bonanza grade gold developed within multiple, 10-30cm wide structures with mineralized margins" said Mr Hudson.  "This set forms only a small part of the samples collected from surface discoveries this summer at Rompas over a very significant strike and width.  The prospectivity of Rompas is now beginning to be revealed."

Source:

Mawson Resources Limited

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.